Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Status:
Terminated
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
The MAURITIUS trial is a single-arm, multicenter phase II study of single treatment with
midostaurin being applied to AML (acute myeloid leukemia) patients with activating FLT3
(FMS-like tyrosine kinase3) mutations and either molecular relapse or persistent molecular
positivity after allogeneic SCT. The leukemia-free survival (LFS), the achievement of "MRD
low" as well as the incidence of GvHD after transplantation reflect the most relevant
endpoints of this non-randomized clinical trial.